The Sainte-Anne Hospital Center is a hospital located in the 14th arrondissement of Paris, specializing in psychiatry, neurology, neurosurgery, neuroimaging and addiction.

During the past decade, GHU Paris Psychiatrie et Neurosciences conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "GHU Paris Psychiatrie et Neurosciences" #1 sponsor was "Boehringer Ingelheim" with 3 trials, followed by "Centre Hospitalier St Anne" with 3 trials sponsored, "Alcediag" with 1 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 1 trials sponsored and "Centre Hospitalier Universitaire de Besancon" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "GHU Paris Psychiatrie et Neurosciences" #1 collaborator was "Ministry of Health, France" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 1 trials as a collaborator, "Centre Hospitalier St Anne" with 1 trials as a collaborator and "Fundacion Clinic per a la Recerca Biomédica" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "GHU Paris Psychiatrie et Neurosciences" are "Schizophrenia" (2 trials), "Bipolar Disorder" (1 trials), "COVID-19" (1 trials), "Child Behavior Disorders" (1 trials) and "Comatose" (1 trials). Many other conditions were trialed in "GHU Paris Psychiatrie et Neurosciences" in a lesser frequency.

Most popular intervention types in "GHU Paris Psychiatrie et Neurosciences" are "Drug" (5 trials), "Device" (2 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "ASA 100 mg" (1 trials), "Antiplatelet therapy" (1 trials), "BI 409306" (1 trials) and "BI 425809" (1 trials). Other intervention names were less common.

The vast majority of trials in "GHU Paris Psychiatrie et Neurosciences" are 10 trials for "All" genders.

Currently, there are NaN active trials in "GHU Paris Psychiatrie et Neurosciences". 2 are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in GHU Paris Psychiatrie et Neurosciences, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in GHU Paris Psychiatrie et Neurosciences, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".